CoChat
Sign Up
Cited by 264Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityAlcohol Consumption and Health Effects

Non-alcoholic fatty liver disease: A patient guideline

Open access
Francque, Sven M., Marchesini, Giulio, Kautz, Achim, Walmsley, Martine, Dorner, Rebecca, Lazarus, Jeffrey V., Zelber-Sagi, Shira, Hallsworth, Kate +11 more·2021·JHEP Reports
DOI 10.1016/j.jhepr.2021.100322PMC PMC8514420
Open this paper in CoChat — free accountOpen PDF

Abstract

This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhepr.2021.100322

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increased physical activity, exercise and reduction in sedentary behaviour, independent of weight loss, has hepatic and cardiometabolic benefit.

    “Therefore, increased physical activity, exercise and reduction in sedentary behaviour, independent of weight loss, has hepatic and cardiometabolic bene fi t and should be routinely recommended. 312,327”

    From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [327]

    The “Physical activity/exercise” section says reducing sedentary time is useful for people with NAFLD and that physical activity reduces liver fat and the risk of metabolic diseases, including T2D and CVD. A cited study’s title in the References states that resistance exercise reduces liver fat independently of weight loss. The guideline does not establish that all the stated hepatic and cardiometabolic benefits of increased activity and reduced sedentary behaviour are independent of weight loss. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 294 · Cited by 264

Research works printed but not linked: 233

  1. [1]Yeh M.M. Brunt E.M. Pathological features of fatty liver disease Gastroenterology 147 2014 754 764 10.1053/j.gastro.2014.07.056 25109884 · DOI
  2. [2]Kwanten W.J. Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue World J Gastroenterol 20 2014 7325 10.3748/wjg.v20.i23.7325 24966603 PMC4064078 · DOI
  3. [4]Kotronen A. Westerbacka J. Bergholm R. Pietiläinen K.H. Yki-Järvinen H. Liver fat in the metabolic syndrome J Clin Endocrinol Metab 92 2007 3490 3497 10.1210/jc.2007-0482 17595248 · DOI
  4. [5]Mazzotti A. Caletti M.T. Sasdelli A.S. Brodosi L. Marchesini G. Pathophysiology of nonalcoholic fatty liver disease: lifestyle-gut-gene interaction Dig Dis (Basel, Switzerland) 34 Suppl 1 2016 3 10 10.1159/000447275 27548720 · DOI
  5. [6]Younossi Z.M. Marchesini G. Pinto-Cortez H. Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation Transplantation 103 2019 22 27 10.1097/TP.0000000000002484 30335697 · DOI
  6. [7]Malhotra P. Gill R.K. Saksena S. Alrefai W.A. Disturbances in cholesterol homeostasis and non-alcoholic fatty liver diseases Front Med 7 2020 467 10.3389/fmed.2020.00467 PMC7492531 32984364 · DOI
  7. [9]Expert Panel on Detection, Evaluation and T of HBC in A Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA 285 2001 2486 2497 10.1001/jama.285.19.2486 11368702 · DOI · Paper page
  8. [10]Alberti K.G.M. Zimmet P. Shaw J. The metabolic syndrome—a new worldwide definition The Lancet 366 2005 1059 1062 10.1016/S0140-6736(05)67402-8 16182882 · DOI · Paper page
  9. [11]Alberti K.G.M.M. Eckel R.H. Grundy S.M. Zimmet P.Z. Cleeman J.I. Donato K.A. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood Institute; American heart association; world heart federation; international Circulation 120 2009 1640 1645 10.1161/CIRCULATIONAHA.109.192644 19805654 · DOI · Paper page
  10. [12]Thursz M. Gual A. Lackner C. Mathurin P. Moreno C. Spahr L. EASL clinical practice guidelines: management of alcohol-related liver disease J Hepatol 69 2018 154 181 10.1016/j.jhep.2018.03.018 29628280 · DOI
  11. [13]Marchesini G. Day C.P. Dufour J.F. Canbay A. Nobili V. Ratziu V. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease J Hepatol 64 2016 1388 1402 10.1016/j.jhep.2015.11.004 27062661 · DOI · Paper page
  12. [14]Chalasani N. Younossi Z. Lavine J.E. Charlton M. Cusi K. Rinella M. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases Hepatology 67 2018 328 357 10.1002/hep.29367 28714183 · DOI · Paper page
  13. [15]Ayonrinde Oyekoya Taiwo Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - reconciling the present with the past JHEP Rep 2021 PMC8135048 34036255
  14. [16]Eslam M. Newsome P.N. Sarin S.K. Anstee Q.M. Targher G. Romero-Gomez M. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement J Hepatol 73 2020 202 209 10.1016/j.jhep.2020.03.039 32278004 · DOI · Paper page
  15. [17]Ratziu V. Rinella M. Beuers U. Loomba R. Anstee Q.M. Harrison S. The times they are a-changin’ (for NAFLD as well) J Hepatol 73 2020 1307 1309 10.1016/j.jhep.2020.08.028 32890593 · DOI
  16. [18]Bedossa P. Poitou C. Veyrie N. Bouillot J.L. Basdevant A. Paradis V. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients Hepatology 56 2012 1751 1759 10.1002/hep.25889 22707395 · DOI
  17. [19]Kleiner D.E. Brunt E.M. Van Natta M. Behling C. Contos M.J. Cummings O.W. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321 10.1002/hep.20701 15915461 · DOI · Paper page
  18. [20]Bedossa P. Burt A.A. Gouw A.H.A. Lackner C. Schirmacher P. Terracciano L. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease Hepatology 60 2014 565 575 10.1002/hep.27173 24753132 · DOI
  19. [21]Angeli P. Bernardi M. Villanueva C. Francoz C. Mookerjee R.P. Trebicka J. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis J Hepatol 69 2018 406 460 10.1016/j.jhep.2018.03.024 29653741 · DOI
  20. [22]Schuppan D. Surabattula R. Wang X.Y. Determinants of fibrosis progression and regression in NASH J Hepatol 68 2018 238 250 10.1016/j.jhep.2017.11.012 29154966 · DOI · Paper page
  21. [23]Long M.T. Massaro J.M. Hoffmann U. Benjamin E.J. Naimi T.S. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 18 2020 10.1016/j.cgh.2019.11.022 1831-1841.e5 PMC7569606 31734449 · DOI
  22. [24]Hagström H. Alcohol consumption in concomitant liver disease: how much is too much? Curr Hepatol Rep 16 2017 152 157 10.1007/s11901-017-0343-0 28706775 PMC5486588 · DOI
  23. [25]Hardy T. Wonders K. Younes R. Aithal G.P. Aller R. Allison M. The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease Contemp Clin Trials 98 2020 106175 10.1016/j.cct.2020.106175 33045403 · DOI
  24. [27]Anstee Q.M. Darlay R. Cockell S. Meroni M. Govaere O. Tiniakos D. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆ J Hepatol 73 2020 505 515 10.1016/j.jhep.2020.04.003 32298765 · DOI · Paper page
  25. [29]Lefere S. Tacke F. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism JHEP Reports: Innovation Hepatol 1 2019 30 43 10.1016/j.jhepr.2019.02.004 PMC7052781 32149275 · DOI · Paper page
  26. [30]Zegers D. Verrijken A. Beckers S. Francque S. Van Camp J.K. Aerts E. Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population Clin Res Hepatol Gastroenterol 40 2016 333 339 10.1016/j.clinre.2015.09.001 26500201 · DOI
  27. [31]Anstee Q.M. Seth D. Day C.P. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease Gastroenterology 150 2017 10.1053/j.gastro.2016.01.037 1728-1744.e7 26873399 · DOI
  28. [32]Albhaisi S. Chowdhury A. Sanyal A.J. Non-alcoholic fatty liver disease in lean individuals JHEP Reports: Innovation Hepatol 1 2019 329 341 10.1016/j.jhepr.2019.08.002 PMC7001558 32039383 · DOI
  29. [33]Blomdahl J. Nasr P. Ekstedt M. Kechagias S. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus Metab Clin Exp 2021 115 10.1016/j.metabol.2020.154439 33246008 · DOI
  30. [37]Haas J.T. Francque S. Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease Annu Rev Physiol 78 2016 181 205 10.1146/annurev-physiol-021115-105331 26667070 · DOI
  31. [38]Rinella M. Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health Hepatology 64 2016 19 22 10.1002/hep.28524 26926530 · DOI
  32. [39]Huang D.Q. El-Serag H.B. Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention Nat Rev Gastroenterol Hepatol 2020 10.1038/s41575-020-00381-6 PMC8016738 33349658 · DOI · Paper page
  33. [40]Younossi Z.M. Koenig A.B. Abdelatif D. Fazel Y. Henry L. Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 64 2016 73 84 10.1002/hep.28431 26707365 · DOI · Paper page
  34. [41]Paradis V. Zalinski S. Chelbi E. Guedj N. Degos F. Vilgrain V. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis Hepatology 49 2009 851 859 10.1002/hep.22734 19115377 · DOI
  35. [43]Kanwal F. Kramer J.R. Mapakshi S. Natarajan Y. Chayanupatkul M. Richardson P.A. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease Gastroenterology 155 2018 10.1053/j.gastro.2018.08.024 1828-1837.e2 PMC6279617 30144434 · DOI · Paper page
  36. [44]Singh S. Allen A.M. Wang Z. Prokop L.J. Murad M.H. Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies Clin Gastroenterol Hepatol 13 2015 643 654 10.1016/j.cgh.2014.04.014 24768810 PMC4208976 · DOI · Paper page
  37. [46]Loomba R. Adams L.A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH Hepatology (Baltimore, Md) 70 2019 1885 1888 10.1002/hep.30946 PMC7504908 31520407 · DOI
  38. [47]Friedman S.L. Neuschwander-Tetri B.A. Rinella M. Sanyal A.J. Mechanisms of NAFLD development and therapeutic strategies Nat Med 24 2018 908 922 10.1038/s41591-018-0104-9 29967350 PMC6553468 · DOI · Paper page
  39. [48]Eslam M. Valenti L. Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact J Hepatol 68 2018 268 279 10.1016/j.jhep.2017.09.003 29122391 · DOI · Paper page
  40. [49]Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome Lancet Diabetes Endocrinol 2 2017 901 910 10.1016/S2213-8587(14)70032-4 24731669 · DOI
  41. [50]Francque S.M. van der Graaff D. Kwanten W.J. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications J Hepatol 65 2016 425 443 10.1016/j.jhep.2016.04.005 27091791 · DOI
  42. [51]Mantovani A. Petracca G. Beatrice G. Csermely A. Tilg H. Byrne C.D. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies Gut 2021 10.1136/gutjnl-2021-324191 gutjnl-2021-324191 33685968 · DOI · Paper page
  43. [52]Musso G. Gambino R. Tabibian J.H. Ekstedt M. Kechagias S. Hamaguchi M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis PloS Med 11 2014 e1001680 10.1371/journal.pmed.1001680 PMC4106719 25050550 · DOI
  44. [53]Targher G. Francque S.M. A fatty liver leads to decreased kidney function? J Hepatol 67 2017 1137 1139 10.1016/j.jhep.2017.08.018 28870673 · DOI
  45. [56]Ratziu V. Goodman Z. Sanyal A. Current efforts and trends in the treatment of NASH J Hepatol 62 2015 S65 75 10.1016/j.jhep.2015.02.041 25920092 · DOI
  46. [58]Siddiqui M.S. Harrison S.A. Abdelmalek M.F. Anstee Q.M. Bedossa P. Castera L. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science Hepatology 67 2018 2001 2012 10.1002/hep.29607 29059456 PMC5906171 · DOI
  47. [61]Prevention C for DC and. Measuring healthy days Population assessment of health-related quality of life vol. 53 2000 Centers for Disease Control and Prevention
  48. [62]Doward L.C. Balp M.M. Twiss J. Slota C. Cryer D. Brass C.A. Development of a patient-reported outcome measure for non-alcoholic steatohepatitis (NASH-CHECK): results of a qualitative study Patient 2020 10.1007/s40271-020-00485-w PMC8357766 33336323 · DOI
  49. [63]Younossi Z.M. Stepanova M. Henry L. Racila A. Lam B. Pham H.T. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD Liv Int 37 2017 1209 1218 10.1111/liv.13391 28211165 · DOI
  50. [64]Dan A.A. Kallman J.B. Wheeler A. Younoszai Z. Collantes R. Bondini S. Health-related quality of life in patients with non-alcoholic fatty liver disease Aliment Pharmacol Ther 26 2007 815 820 10.1111/j.1365-2036.2007.03426.x 17767465 · DOI
  51. [65]Golabi P. Otgonsuren M. Cable R. Felix S. Koenig A. Sayiner M. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL) Health Qual Life Outcom 14 2016 18 10.1186/s12955-016-0420-z PMC4746896 26860700 · DOI
  52. [66]Younossi Z.M. Wong V.W. Anstee Q.M. Romero-Gomez M. Trauner M.H. Harrison S.A. Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes Hepatol Commun 4 2020 1637 1650 10.1002/hep4.1581 33163834 PMC7603531 · DOI
  53. [67]Younossi Z.M. Golabi P. Henry L. A comprehensive review of patient-reported outcomes in patients with chronic liver diseases J Clin Gastroenterol 53 2019 30702486
  54. [69]Younossi Z.M. Blissett D. Blissett R. Henry L. Stepanova M. Younossi Y. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe Hepatology 64 2016 1577 1586 10.1002/hep.28785 27543837 · DOI
  55. [70]O’Hara J. Finnegan A. Dhillon H. Ruiz-Casas L. Pedra G. Franks B. Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study JHEP Rep 2 2020 10.1016/j.jhepr.2020.100142 PMC7397699 32775976 · DOI
  56. [72]Estes C. Anstee Q.M. Arias-Loste M.T. Bantel H. Bellentani S. Caballeria J. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 J Hepatol 69 2018 896 904 10.1016/j.jhep.2018.05.036 29886156 · DOI
  57. [73]Younossi Z.M. Stepanova M. Negro F. Hallaji S. Younossi Y. Lam B. Nonalcoholic fatty liver disease in lean individuals in the United States Medicine 91 2012 23117851
  58. [74]Ye Q. Zou B. Yeo Y.H. Li J. Huang D.Q. Wu Y. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis Lancet Gastroenterol Hepatol 5 2020 739 752 10.1016/S2468-1253(20)30077-7 32413340 · DOI · Paper page
  59. [75]Younes R. Govaere O. Petta S. Miele L. Tiniakos D. Burt A. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut 2021 10.1136/gutjnl-2020-322564 gutjnl-2020-322564 33541866 · DOI · Paper page
  60. [76]Brunt E.M. Janney C.G. di Bisceglie A.M. Neuschwander-Tetri B.A. Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 94 1999 2467 2474 10.1111/j.1572-0241.1999.01377.x 10484010 · DOI · Paper page
  61. [77]McPherson S. Hardy T. Henderson E. Burt A.D. Day C.P. Anstee Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management J Hepatol 62 2015 1148 1155 10.1016/j.jhep.2014.11.034 25477264 · DOI
  62. [78]Zhang E. Wartelle-Bladou C. Lepanto L. Lachaine J. Cloutier G. Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening Eur Radiol 25 2015 3282 3294 10.1007/s00330-015-3731-2 25994191 PMC4836892 · DOI
  63. [79]Lazarus J.v. Ekstedt M. Marchesini G. Mullen J. Novak K. Pericàs J.M. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe J Hepatol 2019 10.1016/j.jhep.2019.08.027 31518646 · DOI
  64. [80]Rinella M.E. Lominadze Z. Loomba R. Charlton M. Neuschwander-Tetri B.A. Caldwell S.H. Practice patterns in NAFLD and NASH: real life differs from published guidelines Ther Adv Gastroenterol 9 2016 4 12 10.1177/1756283X15611581 PMC4699276 26770262 · DOI
  65. [81]de Vries M. Westerink J. Kaasjager K.H.A.H. de Valk H.W. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis J Clin Endocrinol Metab 105 2020 3842 3853 10.1210/clinem/dgaa575 PMC7526735 32827432 · DOI
  66. [82]Boursier J. de Ledinghen V. Leroy V. Anty R. Francque S. Salmon D. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis J Hepatol 66 2017 1158 1165 10.1016/j.jhep.2017.01.003 28088581 · DOI
  67. [83]Boursier J. Tsochatzis E.A. Case-finding strategies in non-alcoholic fatty liver disease JHEP Rep 3 2021 100219 10.1016/j.jhepr.2020.100219 33659890 PMC7896150 · DOI
  68. [84]Byrne C.D. Patel J. Scorletti E. Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults BMJ (Online) 362 2018 10.1136/bmj.k2734 30002017 · DOI
  69. [85]Francque S. Lanthier N. Verbeke L. Reynaert H. van Steenkiste C. Vonghia L. The Belgian association for study of the liver guidance document on the management of adult and paediatric non-alcoholic fatty liver disease Acta Gastroenterol Belg 81 2018 55 81 29562379
  70. [86]Francque S.M.A. Verrijken A. Mertens I. Hubens G. Van Marck E. Pelckmans P. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients Clin Gastroenterol Hepatol 10 2012 1162 1168 10.1016/j.cgh.2012.06.019 quiz e87 22796457 · DOI
  71. [88]Wong R.J. Aguilar M. Cheung R. Perumpail R.B. Harrison S.A. Younossi Z.M. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States Gastroenterology 148 2017 547 555 10.1053/j.gastro.2014.11.039 25461851 · DOI
  72. [89]Bedossa P. Poynard T. An algorithm for the grading of activity in chronic hepatitis C Hepatology 24 1996 289 293 10.1002/hep.510240201 8690394 · DOI
  73. [90]Ratziu V. Charlotte F. Heurtier A. Gombert S. Giral P. Bruckert E. Sampling variability of liver biopsy in nonalcoholic fatty liver disease Gastroenterology 128 2005 1898 1906 10.1053/j.gastro.2005.03.084 15940625 · DOI · Paper page
  74. [91]Kleiner D.E. Bedossa P. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists Gastroenterology 149 2015 1305 1308 10.1053/j.gastro.2015.09.015 26409177 · DOI
  75. [92]Seeff L.B. Everson G.T. Morgan T.R. Curto T.M. Lee W.M. Ghany M.G. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial Clin Gastroenterol Hepatol 8 2010 877 883 10.1016/j.cgh.2010.03.025 20362695 PMC3771318 · DOI
  76. [93]Neuberger J. Patel J. Caldwell H. Davies S. Hebditch V. Hollywood C. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology Gut 69 2020 1382 1403 10.1136/gutjnl-2020-321299 32467090 PMC7398479 · DOI · Paper page
  77. [94]Castera L. Friedrich-Rust M. Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease Gastroenterology 156 2019 10.1053/j.gastro.2018.12.036 1264-1281.e4 PMC7505052 30660725 · DOI · Paper page
  78. [95]Wong V.W.-S. Adams L.A. de Lédinghen V. Wong G.L.-H. Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise Nat Rev Gastroenterol Hepatol 15 2018 461 478 10.1038/s41575-018-0014-9 29844588 · DOI
  79. [96]Ballestri S. Romagnoli D. Nascimbeni F. Francica G. Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications Expert Rev Gastroenterol Hepatol 9 2015 603 627 10.1586/17474124.2015.1007955 25694178 · DOI
  80. [97]Schwenzer N.F. Springer F. Schraml C. Stefan N. Machann J. Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance J Hepatol 51 2009 433 445 10.1016/j.jhep.2009.05.023 19604596 · DOI
  81. [98]Saverymuttu S.H. Joseph A.E. Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis Br Med J 292 1986 13 15 10.1136/bmj.292.6512.13 3080046 PMC1338970 · DOI
  82. [99]Kwok R. Choi K.C. Wong G.L.-H. Zhang Y. Chan H.L.-Y. Luk A.O.-Y. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study Gut 65 2016 10.1136/gutjnl-2015-309265 1359 LP – 1368 25873639 · DOI
  83. [101]Dulai P.S. Sirlin C.B. Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice J Hepatol 65 2017 1006 1016 10.1016/j.jhep.2016.06.005 PMC5124376 27312947 · DOI
  84. [102]Middleton M.S. Heba E.R. Hooker C.A. Bashir M.R. Fowler K.J. Sandrasegaran K. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis Gastroenterology 153 2017 753 761 10.1053/j.gastro.2017.06.005 28624576 PMC5695870 · DOI
  85. [103]Bedogni G. Bellentani S. Miglioli L. Masutti F. Passalacqua M. Castiglione A. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population BMC Gastroenterol 6 2006 33 10.1186/1471-230X-6-33 17081293 PMC1636651 · DOI
  86. [104]Munteanu M. Tiniakos D. Anstee Q. Charlotte F. Marchesini G. Bugianesi E. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference Aliment Pharmacol Ther 44 2016 877 889 10.1111/apt.13770 27549244 PMC5113673 · DOI
  87. [105]Björkström K. Stål P. Hultcrantz R. Hagström H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 15 2017 1461 1468 10.1016/j.cgh.2017.04.040 28479500 · DOI
  88. [106]Bazerbachi F. Haffar S. Wang Z. Cabezas J. Arias-Loste M.T. Crespo J. Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals Clin Gastroenterol Hepatol 17 2019 10.1016/j.cgh.2018.08.069 54-64.e1 30196155 · DOI
  89. [107]Patel K. Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis JHEP Reports: Innovation Hepatol 2 2020 100067 10.1016/j.jhepr.2020.100067 PMC7047178 32118201 · DOI
  90. [108]Boursier J. Francque S. Noninvasive tests of liver fibrosis and their combination in nonalcoholic fatty liver disease: from selected patients to real-life populations Hepatology (Baltimore, Md) 70 2019 1500 1502 10.1002/hep.30886 31381156 · DOI
  91. [109]Castera L. Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics Liver Int 40 2020 77 81 10.1111/liv.14347 32077617 · DOI
  92. [110]Herrmann E. de Lédinghen V. Cassinotto C. Chu W.C.W. Leung V.Y.F. Ferraioli G. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis Hepatology 67 2018 260 272 10.1002/hep.29179 28370257 PMC5765493 · DOI
  93. [112]Hsu C. Caussy C. Imajo K. Chen J. Singh S. Kaulback K. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants Clin Gastroenterol Hepatol 17 2019 10.1016/j.cgh.2018.05.059 630-637.e8 PMC6294709 29908362 · DOI
  94. [113]McPherson S. Stewart S.F. Henderson E. Burt A.D. Day C.P. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease Gut 59 2010 1265 LP – 1269 20801772
  95. [114]Angulo P. Hui J.M. Marchesini G. Bugianesi E. George J. Farrell G.C. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD Hepatology 45 2007 846 854 10.1002/hep.21496 17393509 · DOI
  96. [116]Vali Y. Lee J. Boursier J. Spijker R. Löffler J. Verheij J. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis J Hepatol 73 2020 252 262 10.1016/j.jhep.2020.03.036 32275982 · DOI · Paper page
  97. [117]Harrison S.A. Ratziu V. Boursier J. Francque S. Bedossa P. Majd Z. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study Lancet Gastroenterol Hepatol 5 2020 970 985 10.1016/S2468-1253(20)30252-1 32763196 · DOI
  98. [118]Lee Y.-S. Yoo Y.J. Jung Y.K. Kim J.H. Seo Y.S. Yim H.J. Multiparametric MR is a valuable modality for evaluating disease severity of nonalcoholic fatty liver disease Clin Translational Gastroenterol 11 2020 e00157 10.14309/ctg.0000000000000157 PMC7263657 32251018 · DOI
  99. [119]Schaapman J.J. Tushuizen M.E. Coenraad M.J. Lamb H.J. Multiparametric MRI in patients with nonalcoholic fatty liver disease J Magn Reson Imaging 2020 10.1002/jmri.27292 jmri.27292 PMC8247423 32822095 · DOI
  100. [120]Newsome P.N. Sasso M. Deeks J.J. Paredes A. Boursier J. Chan W.-K. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study Lancet Gastroenterol Hepatol 5 2020 362 373 10.1016/S2468-1253(19)30383-8 32027858 PMC7066580 · DOI
  101. [121]Petta S. Maida M. Macaluso F.S. Di Marco V. Cammà C. Cabibi D. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease Hepatology 62 2015 1101 1110 10.1002/hep.27844 25991038 · DOI
  102. [122]Verlinden W. Francque S. Michielsen P. Vanwolleghem T. Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness Hepatology (Baltimore, Md) 64 2016 1809 1810 10.1002/hep.28610 27118145 · DOI
  103. [123]Koutoukidis D.A. Koshiaris C. Henry J.A. Noreik M. Morris E. Manoharan I. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis Metab Clin Exp 115 2021 10.1016/j.metabol.2020.154455 33259835 · DOI · Paper page
  104. [124]Vilar-Gomez E. Martinez-Perez Y. Calzadilla-Bertot L. Torres-Gonzalez A. Gra-Oramas B. Gonzalez-Fabian L. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis Gastroenterology 149 2015 10.1053/j.gastro.2015.04.005 367-378.e5 25865049 · DOI · Paper page
  105. [126]Musso G. Cassader M. Rosina F. Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials Diabetologia 55 2012 885 904 10.1007/s00125-011-2446-4 22278337 · DOI · Paper page
  106. [127]Rosqvist F. Kullberg J. Ståhlman M. Cedernaes J. Heurling K. Johansson H.E. Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat: a randomized trial J Clin Endocrinol Metab 104 2019 6207 6219 10.1210/jc.2019-00160 31369090 PMC6839433 · DOI
  107. [128]Luukkonen P.K. Sädevirta S. Zhou Y. Kayser B. Ali A. Ahonen L. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars Diabetes Care 41 2018 1732 1739 10.2337/dc18-0071 American Diabetes Association Inc. 29844096 PMC7082640 · DOI · Paper page
  108. [129]Howard B.v. Wylie-rosett J. Sugar and cardiovascular disease: a statement for healthcare professionals from the committee on nutrition of the council on nutrition, physical activity, and metabolism of the American heart association Circulation 106 2002 523 527 10.1161/01.CIR.0000019552.77778.04 12135957 · DOI
  109. [130]Gaby A.R. Adverse effects of dietary fructose Altern Med Rev 10 2005 294 306 16366738
  110. [131]Jensen T. Abdelmalek M.F. Sullivan S. Nadeau K.J. Green M. Roncal C. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease J Hepatol 68 2018 1063 1075 10.1016/j.jhep.2018.01.019 29408694 PMC5893377 · DOI
  111. [132]Mosca A. Nobili V. de Vito R. Crudele A. Scorletti E. Villani A. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents J Hepatol 66 2017 1031 1036 10.1016/j.jhep.2016.12.025 28214020 · DOI · Paper page
  112. [133]Schwarz J.M. Noworolski S.M. Erkin-Cakmak A. Korn N.J. Wen M.J. Tai V.W. Effects of dietary fructose restriction on liver fat, de Novo lipogenesis, and insulin kinetics in children with obesity Gastroenterology 153 2017 743 752 10.1053/j.gastro.2017.05.043 28579536 PMC5813289 · DOI
  113. [134]Schwimmer J.B. Ugalde-Nicalo P. Welsh J.A. Angeles J.E. Cordero M. Harlow K.E. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial J Am Med Assoc 321 2019 256 265 10.1001/jama.2018.20579 PMC6440226 30667502 · DOI
  114. [135]Godos J. Federico A. Dallio M. Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection Int J Food Sci Nutr 68 2017 18 27 10.1080/09637486.2016.1214239 27484357 · DOI
  115. [136]Ivancovsky-Wajcman D. Fliss-Isakov N. Salomone F. Webb M. Shibolet O. Kariv R. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease Dig Liver Dis 51 2019 1698 1705 10.1016/j.dld.2019.06.005 31281067 · DOI
  116. [137]Salomone F. Ivancovsky-Wajcman D. Fliss-Isakov N. Webb M. Grosso G. Godos J. Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease JHEP Rep 2 2020 100069 10.1016/j.jhepr.2020.100069 32195455 PMC7078532 · DOI
  117. [138]Alferink L.J.M. Kiefte-De Jong J.C. Erler N.S. Veldt B.J. Schoufour J.D. de Knegt R.J. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study Gut 68 2019 1088 1098 10.1136/gutjnl-2017-315940 30064987 · DOI
  118. [139]Baratta F. Pastori D. Polimeni L. Bucci T. Ceci F. Calabrese C. Adherence to mediterranean diet and non-alcoholic fatty liver disease: effect on insulin resistance Am J Gastroenterol 112 2017 1832 1839 10.1038/ajg.2017.371 29063908 · DOI
  119. [143]Maskarinec G. Lim U. Jacobs S. Monroe K.R. Ernst T. Buchthal S.D. Diet quality in midadulthood predicts visceral adiposity and liver fatness in older ages: the multiethnic cohort study Obesity 25 2017 1442 1450 10.1002/oby.21868 28745024 PMC5604249 · DOI
  120. [144]Ma J. Hennein R. Liu C. Long M.T. Hoffmann U. Jacques P.F. Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease Gastroenterology 155 2018 107 117 10.1053/j.gastro.2018.03.038 29604292 PMC6035111 · DOI · Paper page
  121. [149]Freedman N.D. Cross A.J. McGlynn K.A. Abnet C.C. Park Y. Hollenbeck A.R. Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort J Natl Canc Inst 102 2010 1354 1365 10.1093/jnci/djq301 PMC2935477 20729477 · DOI
  122. [150]Ioannou G.N. Morrow O.B. Connole M.L. Lee S.P. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population Hepatology 50 2009 175 184 10.1002/hep.22941 19441103 · DOI
  123. [151]Fedirko V. Lukanova A. Bamia C. Trichopolou A. Trepo E. Nöthlings U. Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in s Ann Oncol 24 2013 543 553 10.1093/annonc/mds434 23123507 PMC3551485 · DOI
  124. [152]Yang W. Sui J. Ma Y. Simon T.G. Chong D. Meyerhardt J.A. A prospective study of dairy product intake and the risk of hepatocellular carcinoma in U.S. men and women Int J Canc 146 2020 1241 1249 10.1002/ijc.32423 PMC6872903 31116416 · DOI
  125. [153]Sawada N. Inoue M. Iwasaki M. Sasazuki S. Shimazu T. Yamaji T. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma Gastroenterology 142 2012 1468 1475 10.1053/j.gastro.2012.02.018 22342990 · DOI
  126. [154]Yang Y. Zhang D. Feng N. Chen G.G. Liu J. Chen G.G. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis Gastroenterology 147 2014 1031 1042 10.1053/j.gastro.2014.08.005 25127680 · DOI
  127. [155]Turati F. Trichopoulos D. Polesel J. Bravi F. Rossi M. Talamini R. Mediterranean diet and hepatocellular carcinoma J Hepatol 60 2014 606 611 10.1016/j.jhep.2013.10.034 24240052 · DOI
  128. [157]Bowden Davies K.A. Sprung V.S. Norman J.A. Thompson A. Mitchell K.L. Harrold J.A. Physical activity and sedentary time: association with metabolic health and liver fat Med Sci Sports Exerc 51 2019 1169 1177 10.1249/MSS.0000000000001901 30694971 PMC6542688 · DOI
  129. [158]Jensen M.D. Ryan D.H. Apovian C.M. Ard J.D. Comuzzie A.G. Donato K.A. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society J Am Coll Cardiol 63 2014 2985 3023 24239920
  130. [159]Hallsworth K. Thoma C. Moore S. Ploetz T. Anstee Q.M. Taylor R. Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls Frontline Gastroenterol 6 2015 44 51 10.1136/flgastro-2014-100432 25580206 PMC4283712 · DOI
  131. [160]ACSM ACSM’s Resource Manual for Guidelines for Exercise Testing and Prescription 5th edition 2006 Lippincott Williams and Wilkins
  132. [161]Kistler K.D. Brunt E.M. Clark J.M. Diehl A.M. Sallis J.F. Schwimmer J.B. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease Am J Gastroenterol 106 2011 460 468 10.1038/ajg.2010.488 21206486 PMC3070294 · DOI
  133. [162]Oh S. Shida T. Yamagishi K. Tanaka K. So R. Tsujimoto T. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study Hepatology 61 2015 1205 1215 10.1002/hep.27544 25271091 · DOI
  134. [163]Kwak M.S. Kim D. Chung G.E. Kim W. Kim Y.J. Yoon J.H. Role of physical activity in nonalcoholic fatty liver disease in terms of visceral obesity and insulin resistance Liver Int 35 2015 944 952 10.1111/liv.12552 24684289 · DOI
  135. [164]Ryu S. Chang Y. Jung H.S. Yun K.E. Kwon M.J. Choi Y. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease J Hepatol 63 2015 1229 1237 10.1016/j.jhep.2015.07.010 26385766 · DOI
  136. [165]Keating S.E. George J. Johnson N.A. The benefits of exercise for patients with non-alcoholic fatty liver disease Expert Rev Gastroenterol Hepatol 9 2015 1247 1250 10.1586/17474124.2015.1075392 26289101 · DOI
  137. [167]Gerber L. Otgonsuren M. Mishra A. Escheik C. Birerdinc A. Stepanova M. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study Aliment Pharmacol Ther 36 2012 772 781 10.1111/apt.12038 22958053 · DOI
  138. [168]Golabi P. Locklear C.T. Austin P. Afdhal S. Byrns M. Gerber L. Effectiveness of exercise in hepatic fat mobilization in nonalcoholic fatty liver disease: systematic review World J Gastroenterol 22 2016 6318 6327 10.3748/wjg.v22.i27.6318 27468220 PMC4945989 · DOI
  139. [169]Keating S.E. Parker H.M. Pavey T.G. Baker M.K. Caterson I.D. George J. Objectively quantified physical activity and sedentary behavior in predicting visceral adiposity and liver fat J Obes 2016 2016 10.1155/2016/2719014 PMC5061966 27777796 · DOI
  140. [170]Orci L.A. Gariani K. Oldani G. Delaune V. Morel P. Toso C. Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression Clin Gastroenterol Hepatol 14 2016 1398 1411 10.1016/j.cgh.2016.04.036 27155553 · DOI
  141. [171]Kwak M.S. Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity Kor J Intern Med 33 2018 64 74 10.3904/kjim.2017.343 PMC5768549 29202557 · DOI
  142. [174]Hashida R. Kawaguchi T. Bekki M. Omoto M. Matsuse H. Nago T. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review J Hepatol 66 2017 142 152 10.1016/j.jhep.2016.08.023 27639843 · DOI · Paper page
  143. [175]Keating S.E. Hackett D.A. George J. Johnson N.A. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis J Hepatol 57 2012 157 166 10.1016/j.jhep.2012.02.023 22414768 · DOI
  144. [176]Berzigotti A. Saran U. Dufour J.F. Physical activity and liver diseases Hepatology 63 2016 1026 1040 10.1002/hep.28132 26313307 · DOI
  145. [178]Balducci S. Cardelli P. Pugliese L. D’Errico V. Haxhi J. Alessi E. Volume-dependent effect of supervised exercise training on fatty liver and visceral adiposity index in subjects with type 2 diabetes the Italian Diabetes Exercise Study (IDES) Diabetes Res Clin Pract 109 2015 355 363 10.1016/j.diabres.2015.05.033 26047682 · DOI
  146. [180]MacDonald C.S. Johansen M.Y. Nielsen S.M. Christensen R. Hansen K.B. Langberg H. Dose-response effects of exercise on glucose-lowering medications for type 2 diabetes: a secondary analysis of a randomized clinical trial Mayo Clinic Proc 95 2020 488 503 10.1016/j.mayocp.2019.09.005 32007295 · DOI
  147. [181]Centis E. Moscatiello S. Bugianesi E. Bellentani S. Fracanzani A.L. Calugi S. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease J Hepatol 58 2013 771 777 10.1016/j.jhep.2012.11.031 23201248 · DOI
  148. [182]Dalle Grave R. Calugi S. Centis E. el Ghoch M. Marchesini G. Cognitive-behavioral strategies to increase the adherence to exercise in the management of obesity J Obes 2011 2011 10.1155/2011/348293 PMC2968119 21052533 · DOI
  149. [183]Fabricatore A.N. {A figure is presented}Behavior therapy and cognitive-behavioral therapy of obesity: is there a difference? J Am Diet Assoc 107 2007 92 99 10.1016/j.jada.2006.10.005 17197276 · DOI
  150. [184]Perri M.G. Martin A.D. Leermakers E.A. Sears S.F. Notelovitz M. Effects of group- versus home-based exercise in the treatment of obesity J Consulting Clin Psychol 65 1997 278 285 10.1037//0022-006x.65.2.278 9086691 · DOI
  151. [185]Mangeri F. Montesi L. Forlani G. Grave R.D. Marchesini G. A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity Diabetology Metab Syndr 6 2014 10.1186/1758-5996-6-74 PMC4082296 25045404 · DOI
  152. [186]Younes R. Bugianesi E. NASH in lean individuals Semin Liver Dis 39 2019 86 95 10.1055/s-0038-1677517 30654392 · DOI · Paper page
  153. [187]Hallsworth K. Avery L. Trenell M.I. Targeting lifestyle behavior change in adults with NAFLD during a 20-min consultation: summary of the dietary and exercise literature Curr Gastroenterol Rep 18 2016 1 7 10.1007/s11894-016-0485-1 26908279 PMC4764638 · DOI
  154. [188]Chen F. Esmaili S. Rogers G.B. Bugianesi E. Petta S. Marchesini G. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation Hepatology 71 2020 1213 1227 10.1002/hep.30908 31442319 · DOI
  155. [189]Hallsworth K. Adams L.A. Lifestyle modification in NAFLD/NASH: facts and figures JHEP Rep 1 2019 468 479 10.1016/j.jhepr.2019.10.008 32039399 PMC7005657 · DOI
  156. [191]Durrer Schutz D. Busetto L. Dicker D. Farpour-Lambert N. Pryke R. Toplak H. European practical and patient-centred guidelines for adult obesity management in primary care Obes Facts 12 2019 40 66 10.1159/000496183 30673677 PMC6465693 · DOI · Paper page
  157. [192]Avery L. Exley C. McPherson S. Trenell M.I. Anstee Q.M. Hallsworth K. Lifestyle behavior change in patients with nonalcoholic fatty liver disease: a qualitative study of clinical practice Clin Gastroenterol Hepatol 15 2017 1968 1971 10.1016/j.cgh.2017.06.011 28624648 · DOI
  158. [194]Wadden T.A. McGuckin B.G. Rothman R.A. Sargent S.L. Lifestyle modification in the management of obesity J Gastrointest Surg 7 2003 452 463 10.1016/S1091-255X(03)00048-9 Elsevier Inc. 12763398 · DOI
  159. [195]Grave R.D. Centis E. Marzocchi R. Ghoch M el Marchesini G. Major factors for facilitating change in behavioral strategies to reduce obesity Psychol Res Behav Manag 6 2013 101 110 10.2147/PRBM.S40460 24124398 PMC3794892 · DOI
  160. [196]McTigue K.M. Conroy M.B. Hess R. Bryce C.L. Fiorillo A.B. Fischer G.S. Using the internet to translate an evidence-based lifestyle intervention into practice Telemed E-Health 15 2009 851 858 10.1089/tmj.2009.0036 19919191 · DOI
  161. [197]Moore T.J. Alsabeeh N. Apovian C.M. Murphy M.C. Coffman G.A. Cullum-Dugan D. Weight, blood pressure, and dietary benefits after 12 months of a web-based nutrition education program (DASH for health): longitudinal observational study J Med Int Res 10 2008 10.2196/jmir.1114 PMC2629362 19073541 · DOI
  162. [198]Sousa P. Fonseca H. Gaspar P. Gaspar F. Controlled trial of an Internet-based intervention for overweight teens (Next.Step): effectiveness analysis Eur J Pediatr 174 2015 1143 1157 10.1007/s00431-015-2502-z 25772743 PMC4543424 · DOI
  163. [199]Eagleson R. Altamirano-Diaz L. McInnis A. Welisch E. Jesus S de Prapavessis H. Implementation of clinical research trials using web-based and mobile devices: challenges and solutions BMC Med Res Methodol 17 2017 10.1186/s12874-017-0324-6 PMC5356263 28302050 · DOI
  164. [200]Fortmann A.L. Gallo L.C. Garcia M.I. Taleb M. Euyoque J.A. Clark T. Dulce digital: an mHealth SMS based intervention improves glycemic control in hispanics with type 2 diabetes Diabetes Care 40 2017 1349 1355 10.2337/dc17-0230 28600309 PMC5606313 · DOI · Paper page
  165. [201]Marchesini G. Petta S. Grave R.D. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice Hepatology 63 2016 2032 2043 10.1002/hep.28392 26663351 · DOI
  166. [202]Rasu R.S. Hunter C.M. Peterson A.L. Maruska H.M. Foreyt J.P. Economic evaluation of an Internet-based weight management program Am J Manag Care 1 2010 98 104 20370312
  167. [203]Mazzotti A. Caletti M.T. Brodosi L. Domizio S di Forchielli M.L. Petta S. An internet-based approach for lifestyle changes in patients with NAFLD: two-year effects on weight loss and surrogate markers J Hepatol 69 2018 1155 1163 10.1016/j.jhep.2018.07.013 30290973 · DOI
  168. [204]Khoo J. Hsiang J. Taneja R. Law N.M. Ang T.L. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: a pilot randomized trial Diabetes Obes Metab 19 2017 1814 1817 10.1111/dom.13007 28503750 · DOI · Paper page
  169. [206]Busetto L. Timing of bariatric surgery in people with obesity and diabetes Ann Translational Med 3 2015 94 10.3978/j.issn.2305-5839.2015.03.62 PMC4430740 26015936 · DOI
  170. [208]Lassailly G. Caiazzo R. Buob D. Pigeyre M. Verkindt H. Labreuche J. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients Gastroenterology 149 2015 379 388 10.1053/j.gastro.2015.04.014 25917783 · DOI · Paper page
  171. [210]Toolabi K. Golzarand M. Farid R. Laparoscopic roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy in terms of efficacy and safety: a comparative study during 11-year experience Obes Surg 2021 10.1007/s11695-021-05313-0 33686580 · DOI
  172. [211]Gu L. Chen B. Du N. Fu R. Huang X. Mao F. Relationship between bariatric surgery and gastroesophageal reflux disease: a systematic review and meta-analysis Obes Surg 29 2019 4105 4113 10.1007/s11695-019-04218-3 31630324 · DOI
  173. [212]Nguyen T. Alzahrani T. Mandler A. Alarfaj M. Panjrath G. Krepp J. Relation of bariatric surgery to inpatient cardiovascular outcomes (from the national inpatient sample) Am J Cardiol 144 2021 143 147 10.1016/j.amjcard.2020.12.049 33385354 · DOI
  174. [214]Sjöström L. Peltonen M. Jacobson P. Sjöström C.D. Karason K. Wedel H. Bariatric surgery and long-term cardiovascular events J Am Med Assoc 307 2012 56 65 10.1001/jama.2011.1914 22215166 · DOI · Paper page
  175. [215]Sjöholm K. Pajunen P. Jacobson P. Karason K. Sjöström C.D. Torgerson J. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study Diabetologia 58 2015 1448 1453 10.1007/s00125-015-3591-y 25924987 · DOI · Paper page
  176. [216]Klebanoff M.J. Corey K.E. Chhatwal J. Kaplan L.M. Chung R.T. Hur C. Bariatric surgery for nonalcoholic steatohepatitis: a clinical and cost-effectiveness analysis Hepatology 65 2017 1156 1164 10.1002/hep.28958 27880977 · DOI
  177. [218]Laursen T.L. Hagemann C.A. Wei C. Kazankov K. Thomsen K.L. Knop F.K. Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects World J Hepatol 11 2019 138 249 10.4254/wjh.v11.i2.138 30820265 PMC6393715 · DOI · Paper page
  178. [219]Hagström H. Ekstedt M. Olbers T. Peltonen M. Carlsson L. Bariatric surgery versus standard obesity treatment and the risk of severe liver disease: data from the Swedish Obese Subjects study Clin Gastroenterol Hepatology 2020 10.1016/j.cgh.2020.11.009 33161161 · DOI
  179. [220]Wirth K.M. Sheka A.C. Kizy S. Irey R. Benner A. Sieger G. Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis Ann Surg 272 2020 32 39 10.1097/SLA.0000000000003871 32224733 PMC12243115 · DOI
  180. [221]Hagström H. Ekstedt M. Olbers T. Peltonen M. Carlsson L. Bariatric surgery versus standard obesity treatment and the risk of severe liver disease: data from the Swedish Obese Subjects study Clin Gastroenterol Hepatol 2020 10.1016/j.cgh.2020.11.009 33161161 · DOI
  181. [222]Goh G.B.B. Schauer P.R. McCullough A.J. Considerations for bariatric surgery in patients with cirrhosis World J Gastroenterol 24 2018 3112 3119 10.3748/wjg.v24.i28.3112 30065557 PMC6064959 · DOI
  182. [223]Ahmed S. Pouwels S. Parmar C. Kassir R. de Luca M. Graham Y. Outcomes of bariatric surgery in patients with liver cirrhosis: a systematic review Obes Surg 2021 31 10.1007/s11695-021-05289-x 33595790 · DOI · Paper page
  183. [224]Tsochatzis E. Coilly A. Nadalin S. Levistky J. Tokat Y. Ghobrial M. International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation Transplantation 103 2019 45 56 10.1097/TP.0000000000002433 30153225 · DOI · Paper page
  184. [225]Mikolasevic I. Filipec-Kanizaj T. Mijic M. Jakopcic I. Milic S. Hrstic I. Nonalcoholic fatty liver disease and liver transplantation - where do we stand? World J Gastroenterol 24 2018 1491 1506 10.3748/wjg.v24.i14.1491 29662288 PMC5897854 · DOI
  185. [227]Ascha M.S. Hanouneh I.A. Lopez R. Tamimi T.A.R. Feldstein A.F. Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis Hepatology 51 2010 1972 1978 10.1002/hep.23527 20209604 · DOI · Paper page
  186. [228]Khoudari G. Singh A. Noureddin M. Fritze D. Lopez R. Asaad I. Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort World J Hepatol 11 2019 710 718 10.4254/wjh.v11.i10.710 31749901 PMC6856017 · DOI
  187. [229]Loomba R. Bettencourt R. Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study Aliment Pharmacol Ther 30 2009 1137 1149 10.1111/j.1365-2036.2009.04141.x 19737152 PMC3220929 · DOI
  188. [230]Hart C.L. Morrison D.S. Batty G.D. Mitchell R.J. Smith G.D. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies Br Med J (Online) 340 2010 634 10.1136/bmj.c1240 PMC2837144 20223873 · DOI · Paper page
  189. [231]Mahli A. Hellerbrand C. Alcohol and obesity: a dangerous association for fatty liver disease Dig Dis 34 2016 32 39 10.1159/000447279 27548267 · DOI
  190. [232]Hajifathalian K. Sagvand B.T. McCullough A.J. Effect of alcohol consumption on survival in nonalcoholic fatty liver disease: a national prospective cohort study Hepatology 70 2019 511 521 10.1002/hep.30226 30125379 PMC6380949 · DOI · Paper page
  191. [233]Åberg F. Puukka P. Salomaa V. Männistö S. Lundqvist A. Valsta L. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts Hepatology 71 2020 835 848 10.1002/hep.30864 31323122 · DOI · Paper page
  192. [234]Åberg F. Helenius-Hietala J. Puukka P. Jula A. Binge drinking and the risk of liver events: a population-based cohort study Liver Int 37 2017 1373 1381 10.1111/liv.13408 28276137 · DOI
  193. [235]Ruhl C.E. Everhart J.E. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population Clin Gastroenterol Hepatol 3 2005 1260 1268 10.1016/S1542-3565(05)00743-3 16361053 · DOI
  194. [236]Ekstedt M. Franzén L.E. Holmqvist M. Bendtsen P. Mathiesen U.L. Bodemar G. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease Scand J Gastroenterol 44 2009 366 374 10.1080/00365520802555991 19016382 · DOI
  195. [237]Ajmera V. Belt P. Wilson L.A. Gill R.M. Loomba R. Kleiner D.E. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis Clin Gastroenterol Hepatol 16 2018 10.1016/j.cgh.2018.01.026 1511-1520.e5 PMC6098737 29378307 · DOI
  196. [238]Kim N.H. Jung Y.S. Hong H.P. Park J.H. Kim H.J. Park D il Association between cotinine-verified smoking status and risk of nonalcoholic fatty liver disease Liver Int 38 2018 1487 1494 10.1111/liv.13701 29359396 · DOI
  197. [239]Okamoto M. Miyake T. Kitai K. Furukawa S. Yamamoto S. Senba H. Cigarette smoking is a risk factor for the onset of fatty liver disease in nondrinkers: a longitudinal cohort study PloS One 13 2018 10.1371/journal.pone.0195147 PMC5903610 29664906 · DOI
  198. [240]Rezayat A.A. Moghadam M.D. Nour M.G. Shirazinia M. Ghodsi H. Zahmatkesh M.R.R. Association between smoking and non-alcoholic fatty liver disease: a systematic review and meta-analysis SAGE Open Med 6 2018 10.1177/2050312117745223 205031211774522 PMC5788091 29399359 · DOI
  199. [241]Liu P. Xu Y. Tang Y. Du M. Yu X. Sun J. Independent and joint effects of moderate alcohol consumption and smoking on the risks of non-alcoholic fatty liver disease in elderly Chinese men PloS One 12 2017 10.1371/journal.pone.0181497 PMC5519158 28727853 · DOI
  200. [242]Jung H.S. Chang Y. Kwon M.J. Sung E. Yun K.E. Cho Y.K. Smoking and the risk of non-alcoholic fatty liver disease: a cohort study Am J Gastroenterol 114 2019 453 463 10.1038/s41395-018-0283-5 30353055 · DOI

200 of 233 shown

Authors
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., Dicker, D., Woodward, E., Korenjak, M., Willemse, J., Koek, G. H., Vinker, S., Ungan, M., Mendive, J. M., & Lionis, C.
Affiliations
  • University of Antwerp (BE)
  • University of Bologna (IT)
  • PSC Support (GB)
  • Barcelona Institute for Global Health (ES)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • University of Padua (IT)
  • Clinica Universidad de Navarra (ES)
  • Rabin Medical Center (IL)
  • European Association for the Study of Obesity (GB)
  • Maastricht University Medical Centre (NL)
  • Tel Aviv University (IL)
  • World Organisation of Family Doctors (CN)
  • University of Crete (GR)
Corresponding author
Francque, Sven M.
ORCID
Venue
JHEP Reports
Publisher
Elsevier BV
Published
2021-10
Volume
3
Issue
5
Pages
100322
ISSN
2589-5559 (ISSN-L)
DOI
10.1016/j.jhepr.2021.100322
PMC
PMC8514420
OpenAlex
W3199456866
Cited by
264
References
294
Citations by year
2026: 20 · 2025: 41 · 2024: 72 · 2023: 87 · 2022: 38 · 2021: 4
FWCI
36.21
Type
journal article
Language
en
Update notices
erratum (2024-06-01)
Open access
Licence
Locations
  • JHEP Reports (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (submittedVersion, cc-by-nc-nd)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Funders
  • Gilead Sciences
  • Meso Scale Diagnostics
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, patient education, patient involvement in care, informed decision-making, disease awareness, chronic liver disease, patient-provider interaction, disease management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review